Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 47Leukemia, Myeloid, Acute 25Recurrence 21Lymphoma, Large B-Cell, Diffuse 13Sarcoma 9Lymphoma 6Neoplasms, Plasma Cell 5Neoplasm Metastasis 5Glioblastoma 5Endometrial Neoplasms 5Ovarian Neoplasms 4Neurofibrosarcoma 4Neoplasms 4Melanoma 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Non-Hodgkin 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell 3Liposarcoma 3Glioma 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Waldenstrom Macroglobulinemia 2Thymoma 2Sarcoma, Alveolar Soft Part 2Rhabdoid Tumor 2

Interventions

thymoglobulin 1selinexor 1fludarabine 1Rituximab 1Reverse Transcriptase Polymerase Chain Reaction 1Panobinostat 1Melphalan 1Levetiracetam 1Daunorubicin 1Cytarabine 1Cyclophosphamide 1Busulfan 1Bronchoalveolar Lavage 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chromosome Aberrations × selinexor × Clear all
NCT02403310 2022-10-03

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
21 enrolled
Other hematologic neoplasm

Chromosome Aberrations, Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡